In the wake of new FDA guidance, exciting liquid biopsy (LBx) partnership announcements between Merck and Foundation Medicine, and Caris and ConcertAI, the liquid biopsy industry is experiencing a paradigm shift to accelerate patient access to early and affordable detection and surveillance tests.

Across 2 days, 22 world class industry stakeholders addressed the most important challenges in sensitivity, standardization, reimbursements, clinical utility and collaborations. Attendees left the conference with actionable insights to:

• Unlock the promise of ctDNA as a surrogate biomarker to improve surveillance for a paradigm shift towards achieving personalized treatment options
• Implement innovative & next generation assays, such as microfluids, methylation and fragementomics, to boost sensitivity for more accurate early detection
• Uncover the potential of standardizing liquid biopsy frameworks in early detection & surveillance to turbocharge it as an emerging standard of care for patients
• Grasp the importance of collaborative efforts between various stakeholders, including healthcare professionals, researchers, biopharma & regulators to accelerate test reimbursements for improved patient access
• Bridge the gap between analytical claims and clinical observations to divulge the clinical utility of ctDNA based MRD assessments for clinical implementation